期刊文献+

双膦酸盐类药物性颌骨坏死的治疗现状和研究进展 被引量:1

下载PDF
导出
摘要 双膦酸盐类药物(BPs)是一类人工合成的化合物,可有效抑制破骨细胞的活性和功能,诱导破骨细胞的凋亡。研究提示BPs还具有抗肿瘤作用,BPs能抑制肿瘤细胞的自分泌活动^[1],抑制肿瘤细胞对骨的黏附和侵袭^[2],并能通过促进骨的二次矿化作用,高效修复溶骨病灶^[3],因此该药已广泛用于预防和治疗骨质疏松以及恶性骨骼肿瘤的相关事件,如高钙血症、骨痛、病理骨折及骨转移需要放疗或化疗等。尽管BPs给患者带来了福音,但随之而来的双膦酸盐类药物性颌骨坏死(BRONJ)却凸现出来。
作者 张健
机构地区 天津市口腔医院
出处 《山东医药》 CAS 2012年第32期101-103,共3页 Shandong Medical Journal
  • 相关文献

参考文献25

  • 1Santini D, Vespasiani Gentilucci U, Vincenzi B, et al. The antine- oplastic role of bisphosphonates: from basic research toclinical evi- dence [J]. Annals of Oncology, 2003,14(10) :1468-1476.
  • 2Boissier B, Ferreras M, Peyrucbaud O, et al. Bisphosphonates in- hibit breast and prostate carcinoma cell invasion, an early event in the fmnation of bone metastases [ J ] Cancer Research, 2000,60 ( 11 ) :2949-2954.
  • 3Green JR. Antitumor effects of bisphosphonates [ J ]. Cancer, 2003,97 ( Suppl 3 ) :840-847.
  • 4Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteo- necrosis of the jaw : background and guidelines for diagnosis, staging and management [ J ]. Oral Surg Oral Med Oral Pathol OralRadiol Endod, 2006,102 (4) :433 -41.
  • 5Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteone- crosis of the jaw: a review of 2,400 patient cases [ J]. J Cancer Res Clin Oncol, 2010,136(8) :1117-1124.
  • 6Saussez S, Javadian R, Hupin C, et al. Bisphosphonate-related os- teonecrosis of the jaw and its associated risk factors : a Belgian case series [J]. 2009, Laryngoscope, 119(2) :323-329.
  • 7Ozee|ik O, Cenk Haytae M, Kunin A, et al. hnproved wound heal- ing by low-level laser irradiation after gingivectomy operations: a controlled clinical pilot study [J]. J Clin Periodontol, 2008,35 (3) :250-254.
  • 8Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exJ posed bone (osteoneerosis/osteopetrosis) of the jaws: risk factors,] recognition, prevention, and treatment [ J ]. J Oral Maxillofac,] 2005,63 ( 11 ) : 1567-1575.
  • 9Bedogni A, Saia G, Bettini G, et al. Long-term outcomes of surgi- cal resection of the jaws in cancer patients with bisphosphonate-relat- ed osteonecrosis [ J]. Oral Oncol, 2011,47 (5) :420-424.
  • 10Eckardt AM, Lemound J, Lindhorst D, et al. Surgical Manage- ment of Bisphosphonate-related Osteonecrosis of the Jaw in Onco- logic Patients: A Challenging Problem [ J ]. Anticancer Res, 2011,31 (6) :2313-2318.

二级参考文献24

  • 1Mester E,Szende B,Tots.JG.Effect of low intensity laser radiation,repeatedly administered over a long period,on the skin and inner organs of mice[J].Radiobiol Radiother (Berl)11969,10:371-377.
  • 2Pires Oliveira DA,de Oliveira RF,Zangaro RA,et al.Evaluation of low-level laser therapy of osteoblastic cells[J].Photomed Laser Surg,2008,26:401404.
  • 3Arisu HD,Ttirkbz E,Bala 0.Effects of Nd:YAG laser irradiation on osteoblast cell cultures[J].Lasers Med.Sci,2006,21:175-180.
  • 4Xu M,Deng T,Mo F,et al.Low-intensity pulsed laser irradiation affects RANKL and OPG mRNA expression in rat calvarial cells[J].Photomed Laser Surg,2009,27:309-315.
  • 5Haxsen V,Schikom D,Sommer U,et al.Relevance of Isser irradiance threshold in the induction of alkaline phosphatase in human osteoblast cultures[J].Lasers Med Sci,2008,23:381-384:.
  • 6Stein A,Benayahu D,Maltz L,et al.Low-level laser irradiation promotes proliferation and differentiation of human osteoblasts in vitro[J].Photomed Laser Surg,2005,23:161-166.
  • 7Stein E,Koehn J,Sutter W,et al.Initial effects of lowlevel laser therapy on growth and differentiation of human osteoblast-like cells[J].Wien Klin Wochenschr,2008,120:112-117.
  • 8Petri AD,Teixeira LN,Crippa GE,et al.Effects of lowlevel laser therapy on human osteoblastic cells grown on titanium[j].Braz Dent J,2010,1:491498.
  • 9Sasaki Y,Wang S,Ogata Y.Transcriptional regulation of bone sialoprotein gene by CO2 laser irradiation[J].J Oral Sci,2011,53:51-59.
  • 10Saracino S,Mozzati M,Martinasso G,et al.Superpulsed laser irradiation increases osteoblast activity via modulation of bone morphogenetic factors[J].Lasers Surg Med.2009,41:298-304.

共引文献4

同被引文献27

  • 1彭德清,王志刚,宁昌,傅木昌,李健.伊班膦酸钠治疗恶性肿瘤骨痛临床观察[J].临床肿瘤学杂志,2005,10(4):423-424. 被引量:2
  • 2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[ J]. CA Cancer J Clin, 2013, 63(1) : 11-30.
  • 3Sugie-Oya A, Takakura A, Takao-Kawabata R, et al. Comparison of treatment effects of teriparatide and the bisphosphanate riseonate in an aged, osteopenic, ovariectomized rat model under va- rious clinical conditions[J]. J Bone Miner Metab, 2014, 7(4) :1 -12.
  • 4Russell RG. Bisphosphonates: The first 40 years [ J ]. Bone 2011, 49(1) : 2-19.
  • 5Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events : A com- bined analysis of 3 pivotal, randomised, phase 3 trials[ J]. Eur J Cancer, 2012, 48( 16): 3082-3092.
  • 6Tubiana-Hulin M, Beuzeboc P, Manriac L, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases [ J ]. Bulletin Du Cancer, 2001, 88(7): 701-707.
  • 7Van den Wyngaert T, Huizing MT, Fossion E, et al. Bisphospho- nares in ontology : rising stars or fallen heroes [J].Oneologist, 2009, 14(2): 181-191.
  • 8Rosen LS, Gordon DH, Dugan W, et al. Zoledronic acid is supe- rior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion [ J ]. Cancer, 2004, 100(1) : 36-43.
  • 9Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial[ J]. J Clin Oncol, 2005, 23( 15): 3314 -3321.
  • 10Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases [ J]. Ann Oncol, 2003, 14 (9) : 1399-1405.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部